Could the anti-cancer gene p53 be a target in treating kidney cancer?

A recent paper published in the journal Nature Communications reports on the discovery that one of the most commonly mutated genes in kidney cancer, PBRM1, binds to the activated form of the p53 protein in a specific spot. Disruptions to that process can mutate PBRM1, causing it to lose its ability to hold back cancer. […]

read more

Potential new treatment strategy for kidney cancer

A research study, published online in eLife, has provided new insight into the mechanisms behind the development of clear cell renal cell carcinoma (ccRCC), which could have implications for how ccRCC is treated. The researchers have discovered that changes or mutations in tumour suppressor genes (VHL, PBRM1, KDM5C, SETD2 and BAP1) responsible for slowing down […]

read more

Scientists discover the mechanism for resistance to immunotherapy treatment

Scientists from the Dana-Farber Cancer Institute in Boston, USA, have discovered a genetic mechanism in kidney cancer and melanoma cells that explains the mechanism for resistance to immunotherapy drugs called checkpoint inhibitors. This might help to explain why some people respond to immunotherapy, while others do not. The research is published in two articles in […]

read more

Biomarkers predict kidney cancer treatment outcomes

Two recent studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago this week, suggest that levels of a protein called hepatocyte growth factor (HGF) in the blood, and certain changes (mutations) in the genes called┬áBAP1 and PBRM1 in kidney cancer tumours are promising biomarkers for the prediction of survival […]

read more
Showing all 4 results